Modus Therapeutics presents at småbolagsdagarna
Stockholm, Friday, June 10, 2022. Modus Therapeutics Holding AB ("Modus") announces that the company will participate at aktiespararnas event småbolagsdagarna on June 13, 2022.
On June 13th at 12:00 at the event "Småbolagsdagarna by Aktiespararna", Modus' CEO John Öhd will present the company and the ambition to advance sevuparin in clinical development as a "first-in-class" drug candidate in treatment for sepsis and septic shock.
Modus invites you as a journalist, analyst and shareholder to take part in the live broadcast at www.aktiespararna.se/tv/live . The event is open to everyone and does not require any membership in Aktiespararna. No registration is required to follow the event digitally.
Use the opportunity to ask questions to John, by sending an SMS to 079-347 98 45 or email [email protected] . Your question will be conveyed by Aktiespararna´s moderator during the Q&A session that follows the presentation. You can submit your question now or during the presentation.
INFORMATION
When: 13/6 at 12:00
Live broadcast: www.aktiespararna.se/tv/live
For more information on Modus Therapeutics, please contact:
John Öhd, VD, Modus Therapeutics
Telefon: +46 (0) 70 766 80 97
E-post: [email protected]
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: [email protected]
About Modus Therapeutics and sevuparin
Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.